Results
- Showing results for:
- Reset all filters
Search results
-
Conference paperGoldstein DB, Foote SJ, Hafler DA, et al., 2005,
Discussion
, Pages: 39-45, ISSN: 1528-2511 -
Conference paperAbbas AK, Wijmenga C, Rioux JD, et al., 2005,
Discussion
, Pages: 134-144, ISSN: 1528-2511 -
Conference paperWakeland EK, Goodnow CC, Kuchroo VK, et al., 2005,
Discussion
, Pages: 212-218, ISSN: 1528-2511 -
Conference paperGoldstein DB, Abbas AK, Wijmenga C, et al., 2005,
Discussion
, Pages: 8-13, ISSN: 1528-2511 -
Conference paperWakeland EK, Goodnow CC, Cookson W, et al., 2005,
Discussion
, Pages: 239-241, ISSN: 1528-2511 -
Conference paperHafler DA, Rao A, Ting J, et al., 2005,
Discussion
, Pages: 174-179, ISSN: 1528-2511 -
Journal articleHollax EJ, Davies J, Griesenbach U, et al., 2005,
Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis
, J Negat Results Biomed, Vol: 7 -
Journal articleHilliard T, Edwards S, Buchdahl R, et al., 2005,
Voriconazole therapy in children with cystic fibrosis.
, J Cyst Fibros, Vol: 4, Pages: 215-220, ISSN: 1569-1993BACKGROUND: There is increasing evidence for the efficacy of the antifungal voriconazole, particularly in immunosuppression. We describe our experience of using voriconazole in children with CF. METHODS: We performed a retrospective case note review of children with CF treated with voriconazole in a single centre over an 18 month period. RESULTS: A total of 21 children aged 5 to 16 years (median 11.3) received voriconazole for between 1 and 50 (22) weeks. Voriconazole was used as monotherapy in 2 children with recurrent allergic bronchopulmonary aspergillosis (ABPA); significant and sustained improvements in clinical and serological parameters for up to 13 months were observed, without recourse to oral steroids. Voriconazole was used in combination with an immunomodulatory agent in a further 11 children with ABPA, with significant improvement in pulmonary function and serology. 8 children without ABPA but who had recurrent Aspergillus fumigatus isolates and increased symptoms also received voriconazole; this group did not improve with treatment. Adverse effects occurred in 7 children (33%: photosensitivity reaction 3, nausea 2, rise in hepatic enzymes 1, hair loss 1). CONCLUSIONS: Voriconazole may be a useful adjunctive therapy for ABPA in CF. Voriconazole monotherapy appears to be an alternative treatment strategy when oral corticosteroids may not be suitable.
-
Journal articleAziz ZA, Wells AU, Desai SR, et al., 2005,
Functional impairment in emphysema: Contribution of airway abnormalities and distribution of parenchymal disease
, AMERICAN JOURNAL OF ROENTGENOLOGY, Vol: 185, Pages: 1509-1515, ISSN: 0361-803X- Cite
- Citations: 79
-
Journal articleSafinia L, Datan N, Höhse M, et al., 2005,
Towards a methodology for the effective surface modification of porous polymer scaffolds
, BIOMATERIALS, Vol: 26, Pages: 7537-7547, ISSN: 0142-9612- Cite
- Citations: 82
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
General enquiries
For any enquiries about the Fungal Science Network at Imperial, please contact: